Skp2 overexpression is highly representative of intrinsic biological aggressiveness and independently associated with poor prognosis in primary localized myxofibrosarcomas

Clinical Cancer Research

Volumn 12, Issue 2, 2006, Pages 487-498

  Huang, Hsuan Ying ^a   Kang, Hong Yo ^a   Li, Chien Feng ^b   Eng, Hock Liew ^a   Chou, Shih Cheng ^c   Lin, Ching Nan ^b   Hsiung, Ching Yeh ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; KI 67 ANTIGEN; MESSENGER RNA; MINICHROMOSOME MAINTENANCE PROTEIN 2; S PHASE KINASE ASSOCIATED PROTEIN 2;

ADULT; AGED; ARTICLE; CELL CYCLE; FEMALE; FIBROMYXOSARCOMA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOFT TISSUE SARCOMA; TUMOR VOLUME; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARRIER PROTEINS; CELL CYCLE PROTEINS; CYCLIN A; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DISEASE PROGRESSION; FEMALE; FIBROSARCOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MYXOSARCOMA; NUCLEAR PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, MESSENGER; S-PHASE KINASE-ASSOCIATED PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 31544465982     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1497     Document Type: Article

References (41)

1. Huang HY, Lal P, Qin J, Brennan MF, Antonescu CR. Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol 2004;35:612-21.
2. Mentzel T, Calonje E, Wadden C, et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol 1996;20:391-405.
3. Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer 1977;39:1672-85.
4. Merck C, Angervall L, Kindblom LG, Oden A. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta Pathol Microbiol Immunol Scand Suppl 1983;282:1-40.
5. Borden EC, Baker LH, Bell RS, et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 2003;9:1941-56.
6. 1-S transition by proteolysis of cyclin E and p27Kip1. Biochem Biophys Res Commun 2001;282:853-60.
7. Langner C, von Wasielewski R, Ratschek M, Rehak P, Zigeuner R. Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique. Virchows Arch 2004;445:631-6.
8. Langner C, von Wasielewski R, Ratschek M, Rehak P, Zigeuner R. Expression of p27 and its ubiquitin ligase subunit Skp2 in upper urinary tract transitional cell carcinoma. Urology 2004;64:611-6.
9. Oliveira AM, Nascimento AG, Okuno SH, Lloyd RV. p27(kip1) protein expression correlates with survival in myxoid and round-cell liposarcoma. J Clin Oncol 2000;18:2888-93.
10. Gstaiger M, Jordan R, Lim M, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A 2001;98:5043-8.
11. Sutterluty H, Chatelain E, Marti A, et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999;1:207-14.
12. Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002;110:633-41.
13. Yang G, Ayala G, De Marzo A, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002;8:3419-26.
14. Oliveira AM, Okuno SH, Nascimento AG, Lloyd RV. Skp2 protein expression in soft tissue sarcomas. J Clin Oncol 2003;21:722-7.
15. Nakayama KI, Nakayama K. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol 2005;16:323-33.
16. Lim MS, Adamson A, Lin Z, et al. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood 2002;100:2950-6.
17. Kitajima S, Kudo Y, Ogawa I, et al. Role of Cks1 overexpression in oral squamous cell carcinomas: cooperation with Skp2 in promoting p27 degradation. Am J Pathol 2004;165:2147-55.
18. Shapira M, Ben-Izhak O, Linn S, Futerman B, Minkov I, Hershko DD. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer 2005;103:1336-46.
19. Masuda TA, Inoue H, Nishida K, et al. Cyclin-dependent kinase1 gene expression is associated with poor prognosis in gastric carcinoma. Clin Cancer Res 2003;9:5693-8.
20. Penin RM, Fernandez-Figueras MT, Puig L, Rex J, Ferrandiz C, Ariza A. Over-expression of p45(SKP2) in Kaposi's sarcoma correlates with higher tumor stage and extracutaneous involvement but is not directly related to p27(KIP1) down-regulation. Mod Pathol 2002;15:1227-35.
21. Tachibana KE, Gonzalez MA, Coleman N. Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol 2005;205:123-9.
22. Dudderidge TJ, Stoeber K, Loddo M, et al. Mcm2, Geminin, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 2005;11:2510-7.
23. Gonzalez MA, Finder SE, Callagy G, et al. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol 2003;21:4306-13.
24. Li X, Zhao Q, Liao R, Sun P, Wu X. The SCF (Skp2) ubiquitin ligase complex interacts with the human replication licensing factor Cdt1 and regulates Cdt1 degradation. J Biol Chem 2003;278:30854-8.
25. Idbaih A, Coindre JM, Derre J, et al. Myxoid malignant fibrous histiocytoma and pleomorphic liposarcoma share very similar genomic imbalances. Lab Invest 2005;85:176-81.
26. Mentzel T, van den Berg E, Molenaar WM. Myxofibrosarcoma. In: Fletcher CDM, Unni KK, Mertens F, editors. WHO classification of tumors-pathology and genetics, tumours of soft tissue and bone. Lyon: IARC Press: 2002. p. 102-3.
27. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350-62.
28. Soft Tissue Sarcoma. In: American Joint Committee on Cancer, editor. Cancer Staging Manual, 6th ed. Philadelphia: Lippincott-Raven; 2002. p. 221-8.
29. Oda Y, Takahira T, Kawaguchi K, et al. Altered expression of cell cycle regulators in myxofibrosarcoma, with special emphasis on their prognostic implications. Hum Pathol 2003;34:1035-42.
30. Trovik CS, Bauer HC, Alvegard TA, et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer 2000;36:710-6.
31. Zagars GK, Ballo MT, Pisters PW, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003;97:2530-43.
32. Gronchi A, Casali PG, Mariani L, et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol 2005;23:96-104.
33. De Marzo AM, Fedor HH, Gage WR, Rubin MA. Inadequate formalin fixation decreases reliability of p27 immunohistochemical staining: probing optimal fixation time using high-density tissue microarrays. Hum Pathol 2002;33:756-60.
34. 1 phase. Nat Cell Biol 2004;6:1229-35.
35. Chamovitz DA, Segal D. JAB1/CSN5 and the COP9 signalosome. A complex situation. EMBO Rep 2001;2:96-101.
36. Shintani S, Li C, Mihara M, Hino S, Nakashiro K, Hamakawa H. Skp2 and Jab1 expression are associated with inverse expression of p27(KIP1) and poor prognosis in oral squamous cell carcinomas. Oncology 2003;65:355-62.
37. Yam CH, Fung TK, Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci 2002;59:1317-26.
38. Huuhtanen RL, Blomqvist CP, Bohling TO, et al. Expression of cyclin A in soft tissue sarcomas correlates with tumor aggressiveness. Cancer Res 1999;59:2885-90.
39. Kato H, Miyazaki T, Fukai Y, et al. A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma. J Surg Oncol 2003;84:24-30.
40. Sington JD, Freeman A, Morris LS, et al. Minichromosome maintenance protein in myxofibrosarcoma. Mod Pathol 2004;17:235-40.
41. Yokoi S, Yasui K, Saito-Ohara F, et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol 2002;161:207-16.